Today, the EMCDDA has launched a call for expression of interest in membership of the Scientific Committee of the European Union Drugs Agency (EUDA). The EUDA, which will replace the EMCDDA, will begin operations on 2 July 2024, the day on which its founding regulation enters into application.
The role of the Scientific Committee is to assist the EUDA Management Board and Executive Director by delivering opinions on any scientific matter concerning the agency's activity which they may submit to it.
Each member of the EUDA Scientific Committee will be appointed for a four-year period, which may be renewed once. They are appointed in a personal capacity and, acting in the public interest, will offer opinions independently of the EU Member States and institutions. They will neither seek nor take instructions from any government or from any other body.
Scientific Committee meetings are generally held twice a year at the EUDA premises in Lisbon. Members are expected to attend these meetings, which are conducted in English.
Upon appointment, each member of the EUDA Scientific Committee will sign a declaration of independence in relation to the performance of his/her duties in, and for, this body. They will also sign a written declaration of interest.
Deadline for applications: 17.01.2024
About the EUDA
On 2 July 2024, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) will become the European Union Drug Agency (EUDA) in accordance with Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006. For additional information on the EUDA, please see: New legislation grants Europe stronger powers to tackle current and future drug problems